Skip to main content
Caplight Logo









ATB Therapeutics

ATB Therapeutics

Private
Marche-en-FamenneHealthcare & Life Scienceshttps://atbtherapeutics.com/

Last Round

Series A

Nov 18, 2024

Total Funding Raised

$62.6M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ATB Therapeutics is a biotechnology company that develops a new class of antibody-based targeted therapies, called atbodies, to treat cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

biotechnologyantibody-drug conjugatesADCbiologicsplant-based manufacturingoncologyfusion proteinsdrug discoveryautoimmune diseasemolecular farmingbiopharmacontract manufacturingprecision medicinetherapeutic pipelinebiomanufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ATB Therapeutics Comparables

Compare ATB Therapeutics with similar companies based on industry and business-model similarity.

ATB Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sutro Biopharma Inc
72%
Mersana Therapeutics
69%
Pfizer
68%

ATB Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 18, 2024
SeedDec 23, 2019
SeedJan 1, 2018

Key People

Founding team and executive leadership

Bertrand Magy

COO & Co-Founder

Founding Team

Philippe Vandeput

CFO And Chief Business Officer

Executive Team

ATB Therapeutics Investors

Notable investors and investment history

ATB Therapeutics investors
InvestorRounds
Federal Holding and Investment CompanySeries A
EQT Life SciencesSeries A
NoshaqSeed
Wallonie EntreprendreSeries A
V-Bio VenturesSeries A
VIVES PartnersSeries A
Financière Spin-off LuxembourgeoiseSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 122% MoM, from 522 to 1.2K.

  • Nov 18, 2024

    Raised $57M in Series A funding.

ATB Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ATB Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ATB Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMarche-en-Famenne
Employee Range37
Year Founded2018
Last FundingNov 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?